Marcelle Machluf - Insuline Medical External Director
INSL Stock | ILS 370.50 13.70 3.84% |
Director
Prof. Marcelle Machluf serves as External Director at Insuline Medical Ltd since October 27, 2010. She is a member of the Audit, Compensation and Financial Statements Auditing committees. Prof. Machluf work experience includes the following roles Dean of the Faculty of Biotechnology and Food Engineering at The Technion Israel Institute of Technology and Materials Science Faculty Member at Nanyang Technological University . Prof. Machluf holds a BS degree in Life Sciences from The Hebrew University of Jerusalem, a MS degree in Biomedical Engineering from Ben Gurion University, a Doctorate of Science degree in Chemical EngineeringBiotechnology from Ben Gurion University and has completed a postdoctorial fellowship at the Harvard Medical School. She is the Author of numerous papers and journal papers relating to these Subjects. since 2010.
Age | 53 |
Tenure | 14 years |
Phone | 972 3 930 1094 |
Web | http://www.insuline-medical.com |
Similar Executives
Showing other executives | DIRECTOR Age | ||
Eliyahu AyalonLanciano | Bio View | 71 | |
Lior Shav | Bio View | 41 | |
Jan Jingran | Endymed | 31 | |
Yuan Yibing | Endymed | 41 | |
Lennie Michelson | Intercure | 38 | |
Jackie RosenblumGoren | Bio View | 45 | |
Lee Roth | Endymed | 33 | |
Idan Alfa | Endymed | 32 | |
Yoram Harth | Endymed | 56 | |
Eliane Markowitz | Bio View | 50 | |
Batsheva Elran | Endymed | 59 | |
Lior Vider | Endymed | 41 | |
Avner Barak | Intercure | 58 | |
Ronen Zadok | Endymed | 55 | |
Warren Esanu | Bio View | 71 | |
Gideon Hirschfeld | Intercure | 51 | |
Yoav Waizer | Intercure | 46 | |
Yacha Sutton | Bio View | 64 | |
Yoram Even | Intercure | 46 | |
Yocheved Dvir | Endymed | 65 | |
David Grossman | Intercure | 42 |
Insuline Medical Leadership Team
Elected by the shareholders, the Insuline Medical's board of directors comprises two types of representatives: Insuline Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insuline. The board's role is to monitor Insuline Medical's management team and ensure that shareholders' interests are well served. Insuline Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insuline Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Meir Menachem, Director | ||
Avinoam Nun, Director | ||
Eyal Lewin, CEO | ||
Jacob Harel, Director | ||
Moran SherfBlau, Vice President - Finance | ||
Ofer Mor, Independent Director | ||
Eliyahu Naor, Director | ||
Ron Miron, Independent Director | ||
Tomer Kariv, Member of the Board | ||
Gabriel Bitton, Vice President - Research & Development | ||
Marcelle Machluf, External Director | ||
Arie Yossef, External Director | ||
Ronen Melnik, Chairman of the Board | ||
Amalia Herszkowicz, VP of Bus. Devel. and Global Marketing | ||
Yisrael Gewirtz, Internal Auditor | ||
Arie Yosef, External Director | ||
Amir Gal, Independent Director | ||
Ronen Tsimerman, CFO | ||
Ziv Eisner, Director | ||
Avraham Sarfaty, Director | ||
Yosef Wasserman, Director | ||
David Naim, CFO | ||
Gavriel Biton, Vice President - Research & Development | ||
Doron Birger, Chairman of the Board | ||
Marcel Machluf, External Director | ||
Slomzion Shen, External Director |
Insuline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insuline Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Price To Earning | (40.77) X | |||
Revenue | 40 K | |||
EBITDA | (6.82 M) | |||
Net Income | (7.01 M) | |||
Cash And Equivalents | 1.15 M | |||
Cash Per Share | 2.86 X | |||
Current Ratio | 0.98 X | |||
Book Value Per Share | (0.16) X | |||
Cash Flow From Operations | (7.68 M) | |||
Earnings Per Share | (30.78) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Insuline Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Insuline Medical's short interest history, or implied volatility extrapolated from Insuline Medical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insuline Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Insuline Stock analysis
When running Insuline Medical's price analysis, check to measure Insuline Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insuline Medical is operating at the current time. Most of Insuline Medical's value examination focuses on studying past and present price action to predict the probability of Insuline Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insuline Medical's price. Additionally, you may evaluate how the addition of Insuline Medical to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
CEOs Directory Screen CEOs from public companies around the world | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |